An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
European regulators have approved a higher once-weekly dose of Wegovy for adults with obesity. That means the European Commission has given the green light for doctors in the EU to prescribe a 7.2 mg dose of Wegovy, which is taken as a weekly injection. The approval is about changing the available dose, not introducing a brand-new drug. Wegovy’s active ingredient is semaglutide. Semaglutide is a lab-made version of a natural hormone your gut releases after you eat. This hormone talks to the brain to reduce appetite and slows how quickly your stomach empties, so you feel fuller longer. Semaglutide is already used in lower doses for diabetes (as Ozempic) and at a 2.4 mg weekly dose for weight management under the Wegovy name. The approval decision is based on clinical trial data reviewed by regulators. Those trials compared different doses to see how much weight people lost and whether side effects were acceptable. Higher doses generally lead to greater average weight loss in these studies, but the size of the benefit and the rate of side effects vary. The approval applies to adults with obesity; it doesn’t mean everyone will lose the same amount of weight, and results in trials can differ from what happens in real life. This matters because a higher approved dose gives doctors another tool for patients who haven’t reached their goals on lower doses. For people with obesity, more effective options can reduce health risks like high blood pressure, diabetes, and joint pain. It also affects insurance coverage and patient access in Europe: a formal approval is often needed before health systems will pay for a treatment. There are important caveats and risks. Semaglutide can cause nausea, vomiting, diarrhea, and constipation, especially when doses are increased. Long-term side effects are still being studied, and some people can’t take it — for example, it’s not approved for use in people with a personal or family history of certain thyroid cancers. It’s also not a magic fix: lifestyle changes like diet and exercise remain part of care. Finally, regulatory approval for a dose doesn’t mean it’s automatically affordable or available everywhere. Bottom line: Europe has approved a higher 7.2 mg weekly Wegovy dose for adults with obesity, offering a potentially stronger prescription option, but benefits, side effects, and access will vary by person.
Source: BioPharm International